In a randomized controlled trial that involved MASLD with type 2 diabetes, the use of SGLT-2 inhibitors showed improvement in the liver fibrosis markers (serum 4 collagen 7 s, FIB-4 index, controlled attenuation parameter, and serum ferritin) [81]. Here, SLC5A2 is linked to type 2 diabetes mellitus.